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Abstract
Background: The methylation of DNA is recognized as a key mechanism in the regulation of genomic stability
and evidence for its role in the development of cancer is accumulating. LINE-1 methylation status represents a
surrogate measure of genome-wide methylation.
Findings: Using high resolution melt (HRM) curve analysis technology, we have established an in-tube assay that is
linear (r > 0.9986) with a high amplification efficiency (90-105%), capable of discriminating between partcipant
samples with small differences in methylation, and suitable for quantifying a wide range of LINE-1 methylation
levels (0-100%)–including the biologically relevant range of 50-90% expected in human DNA. We have optimized
this procedure to perform using 2 μg of starting DNA and 2 ng of bisulfite-converted DNA for each PCR reaction.
Intra- and inter-assay coefficients of variation were 1.44% and 0.49%, respectively, supporting the high
reproducibility and precision of this approach.
Conclusions: In summary, this is a completely linear, quantitative HRM PCR method developed for the
measurement of LINE-1 methylation. This cost-efficient, refined and reproducible assay can be performed using
minimal amounts of starting DNA. These features make our assay suitable for high throughput analysis of multiple
samples from large population-based studies.
Background
Epigenetic refers to the study of heritable cellular
changes that leave the DNA nucleotide sequence intact
[1]. Increasingly it is recognized that epigenetic mechan-
isms play an important role in cancer etiology through
alterations in gene activation, chromosomal stability,
and genomic imprinting [2,3]. The methylation of DNA
is recognized as a key epigenetic mechanism in the reg-
ulation of genomic stability and cell growth, and evi-
dence for its role in the development of a wide variety
of cancers is accumulating [4-10].
DNA methylation involves the transfer of a methyl
group to cytosine in CpG (cytosine-phosphate-guanine)
dinucleotide pairs. DNA methyltransferases are enzymes
responsible for either creating or maintaining methyla-
tion patterns [11,12]. Two types of aberrant methylation
patterns have been studied in relation to cancer etiology.
Global hypomethylation, which refers to a genome-wide
decrease in the number of cytosine bases that have been
methylated to form 5-methyl-cytosine at CpG sites, is
recognized as an early and consistent event in colorectal
carcinogenesis [13-15]. Global hypomethylation is often
accompanied by a second fundamental abnormality in
DNA methylation, that is, gene-specific hypermethyla-
tion of CpG islands within the promoter regions of criti-
cal genes, which can lead to transcriptional silencing of
tumor suppressor genes [16].
The majority of CpG nucleotides (about 80%) are
found in repetitive nucleotide sequences, multiple copies
of DNA elements that are normally methylated [17].
LINE-1 (long interspersed nucleotide element-1)
sequences comprise approximately 20% of the genome
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within the context of DNA hypomethylation and early
colorectal cancer development [18,19]. Many studies
have demonstrated that LINE-1 methylation status clo-
sely parallels overall global methylation levels, indicating
that LINE-1 methylation levels represent a valid surro-
gate measure of genome-wide methylation [20-24].
C u r r e n te v i d e n c es u g g e s t st h a tL I N E - 1h y p o m e t h y a -
tion is not a passive change but contributes to neoplas-
tic and other disease processes. While previously
thought to be “junk” DNA, LINE-1 elements are now
recognized as having played a key role in producing
human genomic diversity. Through its retrotransposon
activity, which acts on itself and other interspersed repe-
titive elements, LINE-1 elements have created an esti-
mated 30% of the mass of the human genome [25].
Hypomethylation influences the activity of LINE-1 ele-
ments within the genome in a sequence- and position-
dependent manner. There is also evidence that delayed
or abnormal replication (i.e. independent repair of chro-
mosome breaks) occurs more frequently if the DNA is
hypomethylated [26]. Hypomethylation of LINE-1
sequences may be markers of regions of the genome at
increased risk of error-prone DNA repair. Hypomethyla-
tion increases activity of the bidirectional LINE-1 pro-
moter, and LINE-1 transcripts in cis can suppress the
transcription of genes, including those involved in DNA
repair [27,28]. Kaer et al. [29] found that active intronic
LINE-1 sequences could cause transcriptional interfer-
ence of genes through intron retention, forced exoniza-
tion and cryptic polyadenylation.
All LINE-1 elements are not equally methylated
(reviewed in [28]). Recently, researchers have focused on
LINE-1 loci-specific methylation pattern analysis
whereby individual LINE-1 CpG loci are classified into
one of three classes of distinct methylation levels (hypo-
methylated, partially methylated and hypermethylated).
Hypermethylation and partial methylation is characteris-
tic of the majority of LINE-1 sequences in normal cells,
while increased hypomethylation is observed in cancer.
This repetitive loci-specific methylation measure has
emerged as a promising potential clinical marker for the
detection of cancer-related changes in DNA [28,30].
For the purposes of this research, our goal was to
obtain a surrogate measure of global LINE-1 methyla-
tion based on a representative sub-set of CpG sites
within the LINE-1 consensus promoter region that
could be used as a determinant of risk in cancer predic-
tion. An eventual application of this marker may be to
identify people at higher risk for specific cancer types in
order to target them for screening or intervention pro-
grams. In order to make use of a marker in this manner,
it is necessary to evaluate the relationship between the
marker and cancer risk in large population-based
studies.
The objective of the current investigation was to
design a rapid, reproducible and cost-effective method
to estimate overall LINE-1 methylation that is suitable
for a large population-based study with limited amounts
of DNA available, using high resolution melt (HRM)
curve analysis technology - a quantitative methylation-
sensitive real-time fluorescence-based PCR method
[31-33]. Methods used to quantify global DNA methyla-
tion that were developed prior to HRM are generally
more expensive and labour-intensive, and require larger
amounts of high quality DNA. To date, HRM-based
methods have mainly been used to quantify gene-speci-
fic methylation [31-33]; however, one study used HRM
to measure LINE-1 methylation [34]. In this report we
utilized a Roche LightCycler 480 (LC480) and Gene
Scanning Software, which was originally designed for
Single Nucleotide Polymorphisms (SNP), to develop a
high-throughput and precise assay to obtain an overall
LINE-1 DNA methylation level across a subset of CpG
sites within the LINE-1 repetitive sequence as a surro-
gate measure of global methylation.
Materials and methods
Participant sample collection
A blood sample was collected into a 10 mL EDTA tube
from 13 healthy fasting volunteers. Following collection,
blood was placed on ice, centrifuged within 30 min to
isolate the buffy coat and then stored at -20°C until use.
One additional volunteer provided blood to be used as
the internal control sample for all HRM analyses. All
procedures pertaining to the collection and processing
of samples have been approved by the Queen’sU n i v e r -
sity Health Sciences Research Ethics Board and the
Queen’s University Biohazards Committee. Informed
consent forms were successfully obtained from all parti-
cipants in this report.
Methylation standards
Human Methylated and Non-Methylated DNA stan-
dards were purchased from Zymo Research (Irvine, CA,
USA), and used as received. Unless indicated, 2 μgo f
each standard DNA was bisulfite-converted as described
below. To generate a range of methylated and unmethy-
lated DNA standards, the two Zymo control DNA stan-
dards were mixed in 0, 10, 20, 30, 40, 50, 60, 70, 80, 90
and 100% methylated to unmethylated template ratios.
DNA isolation
DNA was isolated from peripheral blood leukocytes
(buffy coat) and purified using the 5-PRIME DNA isola-
tion kit (Inter Medico, Markham, ON, Canada)
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Purified DNA was stored at -20°C until use.
Bisulfite conversion
For DNA standards and participant samples, purified
DNA was quantified on a NanoDrop ND-2000 UV-Vis
spectrometer (Thermo Scientific, Wilmington, DE,
USA). DNA was bisulfite-converted (BSC) using an
Epitect Bisulfite Conversion Kit (Qiagen, Valencia, CA,
USA) which selectively deaminates cytosine, but not 5-
methyl-cytosine, to uracil. Chemical modification of
this nucleotide leads to a pri m a r ys e q u e n c ec h a n g ei n
the DNA that permits detection of unmethylated cyto-
sines from 5-methyl-cytosine. To test the reliability of
using the NanoDrop to quantify the amount of DNA
after bisulfite conversion, further experiments were
conducted to compare this spectral absorbance method
with qPCR using a commercially available standard
BSC DNA (D5015, Zymo Research, Irvine CA, USA)
supplied at a concentration of 20 ng/μLt op r o d u c ea
qPCR standard curve. Comparisons were performed on
three BSC DNA samples measured in triplicate
(Methylated DNA Standard sample, Unmethylated
DNA Standard sample, and internal control sample).
No statistical difference was observed (p =0 . 1 8 1 4
using Paired t-test) when comparing these two meth-
ods of quantifying amounts of BSC DNA (See Addi-
tional file 1: Figure S-1 and Table S-1 for details). In
addition, qPCR was used to verify that the concentra-
tions of BSC DNA for the 100% and 0% methylated
standards that were used to prepare the HRM standard
curve were equal. The NanoDrop ND-2000 was used
for all subsequent experiments to quantify BSC DNA.
Column-purified BSC DNA was re-quantified on the
NanoDrop ND-2000. All BSC DNA, unless stated
otherwise, was diluted to 1 ng/μLf o ru s ei nP C R .
Influence of amount of starting DNA and BSC DNA
To evaluate the influence of the amount of starting
DNA on LINE-1 methylation, DNA from the internal
control blood was used at concentrations of 0.5, 1.0
and 2.0 μg. Three aliquots of each quantity of genomic
DNA were tested and HRM analysis was done in tripli-
cate on each of the three aliquots of each concentra-
tion. Similarly, the effect of different starting amounts
of template BSC DNA on LINE-1 methylation levels
was tested using 0.1-10 ng of BSC DNA template with
one aliquot analyzed in triplicate for each quantity of
starting BSC DNA.
Details of HRM method and analysis of data
Primer Design
Primers were designed according to the recommenda-
tions of Wojdacz et al. [35-38] in order to minimize
PCR bias. Briefly, primers were designed with the fol-
lowing conditions: i) primers must contain at least a sin-
gle CpG site as far as possible from the 3’ end of each
primer, and ii) when possible, one or more natural thy-
midine nucleotides (T) originating from a non-CpG
cytosine at the 3’ end of each primer, was included.
Inclusion of a CpG site in the 5’ end of the primer per-
mits experimental manipulation of the PCR bias towards
the methylated DNA. The PCR bias can be modified by
varying the annealing temperature during the amplifica-
tion stage of the experiment. Inclusion of a natural thy-
midine increases the likelihood of amplifying only
bisulfite-modified template DNA.
In the present study, primers were designed against
the completely methylated sense strand sequence. The
promoter region of the consensus LINE-1 sequence
(GenBank #: X58075) was used to design primer sets
with PRIMER DESIGNER 2.01 software (Scientific and
Educational Software, Cary, NC, USA). This primer pair
included one CpG dinucleotide in the 5’ end of the for-
ward primer and two CpG dinucleotide pairs at the 5’
end of the reverse primer (Table 1). The 141 bp ampli-
con included a total of 8 CpG dinucleotides between the
primers. The LINE-1 consensus promoter region, from
which our 8 CpG sites of interest were selected, has
been validated as representative of global DNA methyla-
tion status [22].
HRM analysis
PCR amplification of the DNA was carried out using a
Roche LightCycler 480 (Roche Applied Science, Laval,
PQ, Canada) equipped with the Gene Scanning software
(Version 1.5.0). PCR was performed in a 12 μLr e a c t i o n
volume and 2 ng of BSC DNA templates (2 μL) were
added to each well which contained 1 × LightCycler 480
High Resolution Melting (HRM) Master Mix
® (Roche),
3.0 mM MgCl2 and 0.2 μM of each primer. The cycling
protocol conditions included a single enzyme activation
step of 10 min at 95°C followed by 40 cycles of the fol-
lowing steps: denaturation 95°C, 10 s, annealing 48°C,
10 s, and extension 72°C, 15 s. It is important to note
Table 1 Primer Sequence set of LINE-1
Primer sequences (CpG sites in bold) Annealing temperature
(°C)
Amplicon size (bp) Number of CpGs between primers
Primer Set F: 5’-GCGAGGTATTGTTTTATTTGGGA-3’
R: 5’-CGCCGTTTCTTAAACC-3’
54°C 141 8
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LC480-HRM Master Mix was not adopted. Inclusion of
a touchdown PCR protocol would have favoured the
PCR bias towards the higher melting and thermodyna-
mically more stable methylated DNA product.
The high resolution melting (HRM) step was per-
formed after 40 cycles of amplification. The HRM analy-
sis was initiated by denaturing all products at 95°C for 1
min, followed by annealing at 40°C for 1 min. Samples
were quickly warmed to 55°C and then slowly warmed
to 95°C at 0.1°C per second. Fluorescence data were col-
lected at 25 acquisitions per second. The LC480-HRM
Master Mix
® employed a saturating dye (ResolLight™,
Roche) which facilitated the precise measurement of the
melt curves of the amplicons. The Roche Gene Scanning
software was employed for end product analysis. This
algorithm allowed the raw melt curves to be normalized
for fluorescence intensity, and a temperature shift was
applied to align the normalized melt curves, which
facilitated the analysis of samples with varying crossing
point (Cp) values. A difference curve was then derived
from the first derivative of the melt curves. Data for the
difference melt curves were exported to Excel (Office
2007; Microsoft Corp., Redmond, WA, USA) for further
analysis after the graphs were plotted and inverted verti-
cally. Both peak-height and area-under-the-curve from
the normalized, temperature-shifted, difference curves
were used to generate a standard curve and determine
the degree of methylation of each DNA sample.
Methylation analysis of participant samples
All participant DNA samples were analyzed on a 96-well
plate which included a no-template control (NTC), a set
of reference methylation standards, and an inter-assay
internal control sample. Reference methylation standard
curves and experimental samples were tested in tripli-
cate. Standard curves were plotted with Prism (V4.03;
GraphPad Software Inc., La Jolla, CA, USA), and percent
methylation of each test sample was determined by
interpolation of the data generated from the linear
regression analysis of the standard curve from each
plate.
Intra- and inter-assay reproducibility of LINE-1
methylation
To assess reproducibility, blood samples from 13 partici-
pants were analyzed in triplicate on each of three plates.
An identical internal control sample and a set of methy-
lation standards were included on each plate. Objective
criteria were established to determine when individual
participant methylation values would be excluded from
the analysis. For the HRM analysis, the first derivative of
the melt curve was determined for each sample. Repli-
cate samples were aligned and the peak-melt tempera-
ture for each sample within a set of triplicates was
examined. A triplicate methylation value would be
excluded from further analysis if the peak-melt tempera-
ture varied by more than 0.2°C from the other two
remaining triplicate values. In addition, individual out-
liers (> 5% difference from each of the remaining tripli-
cate values) would be removed and the average
methylation value calculated using the remaining
replicates.
The decision to re-run a plate was based on the per-
formance of the internal control sample. The 5% differ-
ence rule described above was applied to the internal
control triplicate values. If the difference between a spe-
cified pre-determined methylation cut-off level for the
internal control (i.e. 90.5% methylation) and the average
methylation value for the remaining internal control
replicates for a specific plate was more than 5%, then
the plate would be repeated.
Intra-assay reproducibility (e.g. within-sample repro-
ducibility) was assessed with a one-way analysis of var-
iance (ANOVA) [39,40]. The repeats of participants on
separate plates were treated as separate samples. To
assess inter-assay reproducibility (e.g. between-plate
reproducibility) an average value was calculated for each
sample on a plate. The coefficient of variation percen-
tage (e.g. CV% = ratio of within-subject variance (Root
mean square error) to the grand mean, multiplied by
100) were used to quantify intra- and inter-assay
reproducibility.
Results
Assessment of methylation standards using HRM
The suitability of using methylation specific (MS)-PCR
for measuring biologically significant levels of LINE-1
methylation was assessed by HRM PCR. Typically, pri-
mer pairs that produce reactions with Cp values of less
than 30 cycles are suitable for subsequent HRM analysis.
As illustrated in Figure 1, the Cp values as determined
by the second derivative maximum of the fluorescence
amplification curves are identical for both the methy-
lated and unmethylated BSC DNA standards. This indi-
cates that there is no PCR bias between the methylated
and unmethylated DNA.
A high resolution melt curve was generated from the
amplified product using only the raw data. Figure 2
shows the raw first derivative of the HRM curve for two
distinct products, the 0% and 100% methylated DNA
standards. The melt curves generated using raw data
displayed a Gaussian distribution, indicating that the
amplicons consisted of a group of PCR products with
similar melt characteristics for each of the methylated
a n du n m e t h y l a t e dD N As t a n d a r d s .T h e1 0 0 %m e t h y -
lated BSC DNA had a melt peak at 77.8°C while the
unmethylated BSC DNA melted at a lower temperature
(75.3°C).
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ally developed for single nucleotide polymorphism
(SNP) analysis, was utilized for end product analysis.
The fluorescence melt curves were scaled and then
normalized for fluorescence intensity. A temperature
shift was then applied to align the normalized melt
curves. The first derivative of the melt curves was cal-
culated and a resultant difference curve plotted. In
this study, a 0% methylated standard was used as the
reference curve.
Deriving the standard curve for determination of LINE-
1methylation
In order to accurately measure the percent methylation
of DNA, a standard curve was established. Various
amounts of BSC methylated and unmethylated DNA
standards were mixed and assayed to produce a stan-
dard curve. HRM PCR was used to amplify BSC DNA
standards. The resultant data were analyzed by the
LC480 Gene Scanning software. The first derivatives of
the difference plots were normalized and temperature-
shifted, and the resultant difference plots for each stan-
dard were plotted in Figure 3. This graph shows that a
range of 0%-100% methylated DNA can be resolved by
this method. More importantly, the standards that
represent biologically relevant methylation levels (50-
90%) of LINE-1 methylation can also be resolved by this
method.
Quantification of LINE-1 methylation
Using the curves from Figure 3, the peak-height
(Figure 4A) and the area-under-the-curve (Figure 4B)
were used to generate two separate standard curves
for quantification of percent methylation in order to
determine which of the above methods was better to
generate a standard curve for subsequent quantifica-
tion. A linear regression analysis was used to plot a
standard curve for subsequent analysis. The correla-
tion coefficient, r = 0.9983, was determined from the
plot of peak-height versus percent methylation, and
the plot of area-under-the-curve versus percent
methylation resulted in a plot with r = 0.9986, indi-
cating a high precision across the full range of DNA
methylation for both peak-height and area-under-the-
curve. As can be seen from this analysis, both peak-
height and area-under-the-curve plots can be used to
quantify methylation. Moreover, both methods of
analysis generate a linear fit which can be readily
applied for accurate determination of LINE-1
methylation.
Figure 2 Raw Melt curves (in triplicates) for 100% methylated
(red) and 100% unmethylated (blue) BSC DNA standards. Melt
curve peaks differed by approximately 2°C and had characteristically
different shapes indicating that the methylated and unmethylated
DNA are different products.
100%Methylation
90%Methylation
80%Methylation
70%Methylation
60%Methylation
50%Methylation
40%Methylation
30%Methylation
20% Methylation 20%Methylation
10%Methylation
0%Methylation
Figure 3 Representative standard curves for the determination
of methylated DNA. Standard samples, from top to bottom, were
100, 90, 80, 70, 60, 50, 40, 30, 20, 10 and 0% methylated. Duplicate
standard curves were plotted for each standard.
Figure 1 Fluorescence curves (in triplicate) of fully methylated
(red) and fully unmethylated (blue) BSC DNA standards.I ti s
important that both methylated and unmethylated DNA are
amplified with similar efficiencies, thereby indicating no PCR bias for
either template DNA.
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Relationship between quantity of starting genomic DNA
and LINE-1 methylation levels
HRM analysis was used to measure the percent
methylation of BSC DNA derived from varying
amounts of starting DNA using the internal control
blood sample. Three aliquots of each DNA starting
amount were analyzed in triplicate. Figure 5 shows
that regardless of the amount of starting DNA (0.5-
2.0 μg) used for bisulfite conversion, the HRM analy-
sis for LINE-1 methylation essentially produced simi-
l a rr e s u l t s .D a t aw e r ea n a l y z e db yo n e - w a yA N O V A
with Tukey’s post hoc t e s t .T h e r ew a sn os i g n i f i c a n t
difference in methylation levels for each starting
amount of DNA. Two μgo fs t a r t i n gD N Aw e r eu s e d
for subsequent analyses using participant blood sam-
ples. The higher amount allowed a more precise
quantification of DNA concentration using the Nano-
drop Spectrometer.
Relationship between amount of BSC DNA template and
LINE-1 methylation
Figure 6 shows a titration curve with varying amounts of
BSC DNA from a blood sample. One aliquot was ana-
lyzed in triplicate for each starting amount of BSC
D N A .T h eC pv a l u e sw e r ed i r e c t l yp r o p o r t i o n a lt ot h e
amount of DNA template from 0.1 to 10 ng. A standard
curve generated from this analysis had a slope of -3.858
and an efficiency of 1.89. Data were analyzed by one-
way ANOVA with Tukey’s post hoc test. No significant
difference was determined between any of the groups,
however the standard deviation of each sample was lar-
ger in the 0.1, 0.5 and 1.0 ng samples.
To further test the reliability of HRM for measuring
methylation using lower amounts of BSC DNA, addi-
tional experiments were conducted comparing methyla-
tion levels for 13 participants using 0.5 ng versus 2.0 ng
of starting BSC DNA. No statistical difference in methy-
lation values was observed (p =0 . 2 6 7 3u s i n gt h eP a i r e d
t-test) indicating that reliable methylation results can be
obtained using this method with as little as 0.5 ng of
starting BSC DNA.
In the current report, in order to reduce the standard
deviation for a given sample, 2 ng of BSC DNA was
chosen as the optimal amount for further experiments
using methylation standards and participant samples.
Similarly, individual aliquots of internal control DNA
were prepared using 2 μgo fs t a r t i n gD N Aa n d2n go f
BSC DNA for each subsequent HRM analysis.
A)
B)
Figure 4 A linear regression plot of the standard curves
against percent methylation.(A) A plot of peak-height versus
percent methylation (r = 0.998). (B) A plot of area-under-the-curve
versus percent methylation (r = 0.998). For this analysis, prepared
standard samples with 0, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100%
methylation were analyzed. All data points were plotted as mean of
triplicate samples ± S.D. Due to minimal variation in triplicate
measures, error bars were not visible in the plot.
Figure 5 Relationship between the starting amount of
genomic DNA used for bisulfite conversion and percent
methylation. Column-purified BSC DNA was diluted to 1 ng/μL and
used as a DNA template for HRM analysis for LINE-1 methylation.
Values are expressed as mean percent ± S.D.
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samples
Percent LINE-1 methylation in the 13 healthy partici-
pants, aged 42-64, ranged from 79.98% to 87.51% with a
mean of 83.70%. The shape and pattern of the melt
curves for participant samples was similar to the stan-
dard curves (See Additional file 2: Figures S-2 and S-3).
The evaluation of intra-assay and inter-assay reprodu-
cibility of this method is presented in Table 2. Each
plate included a set of reference methylation standards,
an internal control sample and participant samples.
Each sample was done in triplicate. Objective criteria
(described in Materials and Methods) were used to
determine when to reject individual sample methylation
values or entire plates. In this experiment, none of the
triplicate values or plates was rejected.
In the evaluation of reproducibility of replicates within
a plate (within-subject or intra-assay variation) the
blood samples from each of the 13 participants on each
of the 3 plates were treated as separate samples. As a
result, this analysis included 39 samples with 3 replicates
for each sample. The coefficient of variation was 1.44%
(Table 2).
To assess the inter-assay (between-plate) reproducibil-
ity, blood samples from each of the 13 participants were
analyzed in triplicate on 3 separate plates and an aver-
age value was obtained for each sample on each plate.
The inter-assay coefficient of variation (inter-assay varia-
tion) was 0.49%.
Discussion
The analysis of repetitive elements in the human gen-
ome by PCR-based methods is a challenge as success
requires identification of consensus primers and amplifi-
cation conditions which can accommodate the sequence
variation of the many copies of the repeat. The quantita-
tive analysis of the methylation status of repetitive ele-
ments is technically more complex because of the need
to bisulfite modify the DNA prior to amplification,
which compounds the variability of the target sequences,
along with the need for the assays to be as reproducible,
precise and efficient as the equivalent analysis of single
copy sequences.
We have established a refined, rapid and reproducible
HRM PCR method that is suitable for quantifying global
LINE-1 methylation in DNA isolated from peripheral
blood leukocytes as a surrogate marker for measurement
of global genomic methylation. Our method is linear,
quantitative and highly repeatable. This relatively simple,
single in-tube assay is capable of discriminating between
participant samples with small differences in methyla-
tion values and quantifying a wide range of LINE-1
A) A)
B)
Figure 6 Relationship between the amount of BSC DNA
template from blood and LINE-1 methylation. The amount of
BSC DNA was varied (left to right, 10 (red), 5 (blue), 2.0 (green), 1
(purple), 0.5 (light blue) and 0.1 ng (light green)) and HRM was used
to measure LINE-1 methylation. (A) Fluorescence curves for varying
amounts of DNA. Each sample was analyzed in triplicate. Note that
at 40 cycles, the 0.1 ng curve did not fully reach a plateau. (B)
Determination of percent methylation as a function of amount of
template BSC DNA. Values are expressed as mean percent ± S.D.
Data were analyzed by one-way ANOVA with Tukey’s post hoc test.
Table 2 Reproducibility of LINE-1 methylation
Samples Range of
Std Dev
Root Mean Square Error Grand
Mean
CV%
Intra-assay variation* 39 0.14-2.29 1.21 83.70% 1.44%
Inter-assay variation** 13 0.10-0.70 0.41 83.70% 0.49%
*Analysis included 3 replicates for each of the 13 participants on each of 3 plates (39 samples)
**Averages of 3 replicates for each of the 13 participants were compared between 3 plates (13 samples)
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values that we observed (approx. 80-88% with a mean of
84%) was consistent with blood leukocyte methylation
values reported by Zhu et al. [41]. We have optimized
the procedure so that it is possible to perform this assay
using as little as 0.5 μgo fs t a r t i n ga m o u n to fD N Ap e r
bisulfite conversion reaction and 0.5 ng of BSC DNA
per PCR reaction while retaining an amplification preci-
sion of greater than 99% and efficiency between 90 and
105%. Both the intra-assay and inter-assay coefficients of
variation were below 1.5%, supporting the high reprodu-
cibility and precision of this approach.
DNA methylation plays an essential role in maintain-
ing cellular function, and changes in global methylation
levels may contribute to the development of cancer. Sev-
eral methods have been developed to quantify global
DNA methylation [16,42-44] including enzymatic diges-
tion followed by high performance liquid chromatogra-
phy (HPLC) [45], traditionally considered to be the ‘gold
standard’, and high performance capillary electrophor-
esis (HPCE) [46]. These techniques are generally expen-
sive, labour-intensive and require fairly large amounts of
starting DNA. Also, given that many population-based
studies have large numbers of participant samples and
often limited amounts of DNA, using these methods to
measure methylation may be cost-prohibitive and tech-
nically challenging.
Methylation of the promoter region of LINE-1 repe-
titive elements has been investigated as a surrogate
marker for global methylation levels using varied
experimental approaches,i n c l u d i n gP C R - b a s e d
methods such as Combined Bisulfite Restriction Analy-
sis (COBRA), MethyLight and pyrosequencing
[22,41,46-51]. These PCR-based methods use bisulfite-
treated DNA in order to differentially modify methy-
lated and non-methylated DNA. The COBRA assay
uses amplification of bisulfite-modified DNA followed
by restriction endonuclease digestion. A limitation of
this method is the need for specific restriction enzyme
recognition sequences within the target region. LINE-1
methylation levels quantified using MethyLight, a
quantitative real-time Taqman-based assay, were highly
correlated with genome-wide LINE-1 methylation as
measured using HPLC [22]. Drawbacks to this method
however are the need to use more costly Taqman
dual-labeled hydrolysis probes and a reference assay
for normalization [22]. Pyrosequencing has been used
extensively for LINE-1 methylation analysis [41,50,51].
While pyrosequencing provides reliable counts of the
methylation status at each CpG dinucleotide site
within a small target region it does require specialized
equipment. In addition, pyrosequencing is not able to
provide information on the context of the methylation
status of each site with respect to the others on the
same DNA strand. Therefore subpopulations of
sequences which exhibit very different methylation pat-
terns cannot be distinguished.
High Resolution Melt analysis PCR (HRM PCR) is
gaining acceptance as a robust method for measuring
levels of methylation [52,53]. HRM utilizes the charac-
teristics of the shape of the melting curve of BSC DNA
to quantify methylation levels. By comparing a series of
BSC dilution curves derived from varying mixtures of
methylated and unmethylated DNA standards, the
degree of methylation in a test sample can be deter-
mined [54]. HRM technology has primarily been used to
quantify single site gene-specific DNA methylation
[28,31,32]. Only one previous study has applied the
HRM technology to measuring LINE-1 methylation in a
variety of biological sample types [34]. Stanzer et al. [34]
reported a high correlation between results obtained
using HRM analysis compared to pyrosequencing and
MethyLight analysis. However, the authors commented
on achieving a modest linear dynamic range. Our study
expands on the seminal work of Stanzer et al. [34] and
provides additional experimental details useful for the
adoption of this approach by other researchers.
There are limitations to HRM for analysis of LINE-1
methylation. For HRM studies of repetitive elements,
the number of genomic targets is large. If a small pro-
portion of the sequences present are extremely hypo- or
hyper-methylated it may not be possible to distinguish
them from the majority of LINE-1 targets [28,48]. In
our study, the consistency of participant and standard
HRM curves suggests that the level of methylation at
the LINE-1 CpG sites of interest was uniform (See
Additional file 2: Figures S-2 and S-3). A further poten-
tial limitation of our assay is the small number of CpG
sites in the LINE-1 repetitive sequence that were ana-
lyzed. In order to maintain a high PCR efficiency, pri-
mers were designed to amplify the smallest fragment
needed to include the 8 CpG dinucleotides in the target
region. In support of this approach, the CpG sites within
the LINE-1 promoter region that we selected have been
validated by other methods as being representative of
the total genomic methylation status [22].
Next generation sequencing (i.e., deep sequencing) is
now permitting the study of entire genomes or targeted
portions of genomes [55]. Through this technology, the
location, sequence variation and methylation patterns of
LINE-1 sequences and other repetitive elements
throughout the genome are being established. While the
detail on the heterogeneity of DNA methylation of
LINE-1 and other sequences obtained with next genera-
tion sequencing technology will be unrivaled, at this
time it is a costly approach for population-based studies
which can require the assessment of thousands of sam-
ples. HRM technology provides a cost-effective and
Tse et al. BMC Research Notes 2011, 4:565
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Page 8 of 10flexible means to survey the methylation status of single
or multiple sites of interest, including repetitive ele-
ments, to identify potential markers of risk in studies of
cancer prediction, or as a companion to other genomic,
proteomic or metabolomic strategies to further under-
stand the role of methylation in the normal functioning
of the genome or in disease pathogenesis.
Conclusion
In summary, we have established a refined, rapid and
reproducible HRM-based method for the quantification
of global LINE-1 repetitive element methylation that is
able to address many of the technical, analytical and
logistical challenges previously encountered. This assay
covers the full range of methylation levels, and most
importantly, methylation in the biologically relevant
range of 50-90% in human DNA samples can be reliably
quantified. The assay is linear, precise and efficient
within parameters acceptable for any quantitative PCR-
based assay using as little as 0.5 μg of starting DNA and
0.5 ng of BSC DNA for each PCR reaction. These fea-
tures make our assay suitable for automation and rapid
high-throughput analysis of multiple samples from large
population-based studies. The use of this method in epi-
genetic research can be extended to the measurement of
methylation levels of single copy sequences and other
repetitive elements.
Additional material
Additional file 1: Figure S-1; Table S-1. LINE-1 qPCR standard curve.
Standard universal methylated bisulfite-converted DNA (20 ng/μL) (Cat. #:
D5015, Zymo Research Corporation) was diluted with nuclease free water
to produce a standard curve for the qPCR. DNA concentration was
determined using the Absolute Quantification routine of the Roche LC-
480 Software and our LINE-1 primer set. The latter is essential as we have
demonstrated that this primer set does not have a PCR bias towards
either methylated or unmethylated DNA. Cycling parameters for the
qPCR were described in the Materials and Methods section and identical
to the conditions of the HRM PCR; Table S1: Quantification of BSC DNA
using UV spectrometry and qPCR. DNA concentration measured with the
NanoDrop ND-2000 UV-VIS spectrometer were compared with values of
DNA concentration measured by qPCR. Paired t-test analysis of the
results from the two methods of quantification showed no significant
difference between the concentration of DNA measured. These results
demonstrated that the NanoDrop ND-2000 spectrometer is an accurate
method for quantifying BSC DNA for HRM analysis.
Additional file 2: Figures S-2 and S-3. Supplemental Figure S-2. Raw
melt curves of 80, 90 and 100% methylation standard. This figure
demonstrates the homogeneity of melt curves from 80, 90 and 100% of
methylation standards, all in triplicates. Supplemental Figure S-3. Raw
melt curves of blood sample from each of 13 subjects used in the
current study. This figure demonstrates the homogeneity of melt curves
in all subjects.
Abbreviations
HRM: High resolution melt; LINE-1: Long interspersed nucleotide element-1;
MS PCR: Methylation specific PCR; BSC DNA: Bisulfite-converted DNA; SNP:
Single nucleotide polymorphism; MALDI-TOF MS: Matrix assisted laser
desorption/ionization time of flight mass spectrometry; HPLC: High
performance liquid chromatography; HPCE: High performance capillary
electrophoresis; COBRA: Combined bisulfite restriction analysis.
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